We are creating centers of excellence in dermatology, oncology and respiratory therapy. The effort is to develop advance therapies to enrich the lives of patients worldwide.

Our Therapeutic Strength

Our journey began 40 years ago with the first product ‘Candid’ which has stood the test of time to remain a market leader across multiple geographies till date. We are committed to ensuring patients get the best treatment available by developing breakthrough medicines in this therapy segment.

Along with dermatology, we are also creating centers of excellence in oncology and respiratory therapy to develop advance medication that enrich lives of patients worldwide. Our recent partnership with Celon for generic Seretide reinforces our growing capabilities in the respiratory segment and is a significant step forward towards building a strong respiratory franchise in Europe.

We launched India’s first digital dose inhaler ‘Digihaler’ a next-gen inhaler which provides an accurate digital dose counter along with low dose warning indicator to enable asthma and chronic obstructive pulmonary disease (COPD) patients to track adherence to their treatment. 

Despite numerous scientific breakthroughs, cancer still claims millions of lives, which is why we constantly endeavor to redefine treatment of cancer by producing life changing medicines. Our scientists have developed three promising clinical candidates targeting oncology indications using BEAT® - our propriety best-in-class platform.

Today, we have a strong team of over 800 scientists in our R&D centers who are dedicated to finding new ways to enrich lives of patients and their families across the world.View our complete list of therapies